Advertisement
Advertisement

VKTX

VKTX logo

Viking Therapeutics, Inc

29.05
USD
Sponsored
-1.19
-3.94%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

29.10

+0.05
+0.17%

VKTX Earnings Reports

Positive Surprise Ratio

VKTX beat 22 of 40 last estimates.

55%

Next Report

Date of Next Report
Feb 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.91
Implied change from Q3 25 (Revenue/ EPS)
--
/
+12.35%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+184.38%

Viking Therapeutics, Inc earnings per share and revenue

On Oct 22, 2025, VKTX reported earnings of -0.81 USD per share (EPS) for Q3 25, missing the estimate of -0.69 USD, resulting in a -17.20% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.96% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 analysts forecast an EPS of -0.91 USD, with revenue projected to reach -- USD, implying an increase of 12.35% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Viking Therapeutics, Inc reported EPS of -$0.81, missing estimates by -17.2%, and revenue of $0.00, 0% as expectations.
The stock price moved up 7.96%, changed from $31.42 before the earnings release to $33.92 the day after.
The next earning report is scheduled for Feb 11, 2026.
Based on 19 analysts, Viking Therapeutics, Inc is expected to report EPS of -$0.91 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement